"Medical quick reading society" won Pfizer's first anti-cancer drug, imitated Tianshili and brought him into the Bureau in dalafei

Phase III clinical failure of Jak1 inhibitor GVHD; acquisition of 51% equity of Longzhong Pharmaceutical Co., Ltd by 140 million yuan of traditional Chinese medicine; approval of BMS and abelpur injection of Xiansheng Pharmaceutical Co., Ltd to be approved; new upgraded metformin to be listed in China Daily fresh medicine news, speed reading club and you pay attention to! On February 2, the national health and Health Commission issued the regulations on the management of internal price behavior in medical institutions, which will be implemented as of the date of promulgation This regulation is applicable to all kinds of public medical institutions at all levels, and non-public medical institutions can also refer to it; the internal price behavior management of medical institutions refers to the internal management of price behaviors such as medical service items, drugs and medical consumables in the diagnosis and treatment activities of medical institutions (National Health and Health Commission) A few days ago, Chinese traditional medicine announced that the company, through its subsidiary Guangdong Yifang Pharmaceutical Co., Ltd., which holds 87.3% of the shares, signed an investment agreement with Gansu Provincial Hospital of traditional Chinese medicine, the shareholder of Gansu Longzhong Pharmaceutical Co., Ltd on December 30, 2019, and transferred 51% of the shares of Gansu Longzhong pharmaceutical held by Gansu Provincial Hospital of traditional Chinese medicine at a price of 139 million yuan (announcement of Chinese traditional medicine) On Tuesday, step pharmaceutical announced that its wholly-owned subsidiary, step Shenzhou pharmaceutical, had recently received the notice on the project approval of 2019 annual implementation plan for major new drug creation and technology major projects issued by the Research Center for medical and health science and technology development of the national health and Health Commission The main research content of this project will take the research and development of new varieties of innovative antibody drugs as the main line, and establish innovative antibody drugs and their key technology systems, such as the discovery and preparation of innovative antibody drugs, drug resistance evaluation, clinical and transformation research, industrialization, etc (step pharmaceutical announcement) On Tuesday, Baiji Shenzhou announced the global tumor strategic cooperation and equity investment with Amgen At the same time, Amgen has completed the acquisition of about 20.5% shares in Baiji Shenzhou According to the terms of cooperation, Baiji Shenzhou will be responsible for the commercialization and development of Amgen's three approved or declared cancer drugs in China, namely, agavir? Desumab injection, kyprolis? Kafzomib for injection and blincyto? Belintomolobib for injection Baiji Shenzhou and Amgen will cooperate to develop 20 Amgen anti-tumor pipeline drugs under research, among which Baiji Shenzhou will be responsible for the development and commercialization in China (Baiji Shenzhou announcement) On March 3, Tianshili announced that tadalafei, a wholly-owned subsidiary of Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., had received the approval document for drug registration issued by the State Food and Drug Administration and became the fourth domestic enterprise with the approval document According to the announcement, after CDE technical review, the product of the company has achieved the same quality and efficacy as the original reference preparation The second batch of 33 varieties purchased in volume involves tadalafil tablets (20mg), and Tianshili will be eligible to participate in the bidding after being approved (notice of Tianshili) On March 3, Huahai pharmaceutical released a notice saying that anlishentan tablet (5mg) had recently received the approval document for drug registration issued by the State Food and drug administration, and was officially approved for listing The drug was declared as per four types of registration, which was deemed to have passed the consistency evaluation (Huahai pharmaceutical announcement) On February 2, PetroChina group issued two consecutive Announcements: sunitinib malate capsule (12.5mg) developed by the subsidiary of PetroChina group Ouyi Pharmaceutical Co., Ltd has obtained the drug registration approval issued by the State Food and drug administration, which is the first approved generic drug in China; pramipexole hydrochloride tablets (0.25mg, 1.0mg) developed by the group Ouyi Pharmaceutical Co., Ltd have obtained the drug registration approval issued by the State Food and drug administration The first one was deemed to have passed the consistency evaluation of quality and efficacy of generic drugs (announcement of Shiyao group) Baiyang pharmaceutical, a subsidiary of Baiyang Pharmaceutical Group, received the drug registration approval document approved and issued by China National Drug Administration (nmpa), and approved the company's osmotic pump metformin Neda ® to be listed Baiyang pharmaceutical's osmotic pump metformin was listed on the market, which filled the gap of domestic market of osmotic pump controlled-release dosage form metformin (Baiyang pharmaceutical announcement) On March 3, Taiji Group announced that southwest pharmaceutical, the holding subsidiary of the company, had received the acceptance notice for the clinical trial of morphine hydrochloride sustained release tablets (24 osmotic pump type) approved and issued by the State Food and drug administration (Taiji group announcement) The application for class 3 generic listing of zuelacetan injection (acceptance No cyhs1700156), the first antiepileptic drug of Jichuan Pharmaceutical Group, has been reviewed and approved, and has entered the stage of "certificate preparation completion - pending approval" It is expected to be approved in the near future If it is approved according to the new classification, it will be deemed as having been evaluated (meter net) Recently, the listing application (acceptance No.: jxss1800015) of Squibb "abamipo injection" has been changed to "under approval", and it is expected to be approved for listing in the near future In July 2013, Squibb and Jiangsu Xiansheng Pharmaceutical Co., Ltd reached a cooperation on the R & D of this variety in the Chinese market After being approved, the two sides shared their market earnings (Insight database) Today, Incyte announced that its selective Jak1 inhibitor itacitinib failed to reach the trial end point in a phase III clinical trial of acute graft-versus-host disease called gravitas-301 In this study, we compared the response rates of itacitinib and placebo on the background of steroids for 28 days in patients who had not received treatment before Results the response rates of the two groups were 74% and 66%, respectively, which failed to reach statistical differentiation A key secondary end point, 6-month non recurrent mortality, was also not differentiated between the two groups (source of us and Chinese Medicine) Deqi pharmaceutical announced today that the food and Drug Administration of the Ministry of health and welfare of Taiwan approved the launch of phase I open clinical trial of PAK4 / Nampt double target oral modulator atg-019 (medicine cube) Recently, accelerator pharma and fulcrum therapeutics jointly announced a research and development cooperation agreement Based on fulcrum's proprietary small molecule regulatory gene expression technology platform, the two sides will jointly develop lung disease treatment drugs targeting specific lung pathways (yaomingkant)